| Oct 27 |
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable
|
| Oct 19 |
Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline
|
| Oct 17 |
Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares
|
| Oct 2 |
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
|
| Sep 27 |
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
|
| Sep 26 |
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study
|
| Sep 26 |
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
|
| Sep 3 |
Enanta Pharmaceuticals to Participate in Investor Conferences in September
|
| Aug 9 |
Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now?
|
| Aug 7 |
Enanta Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
|
